ONCOLYTICS BIOTECH INC

Wang Xiaodong’s recent buy of Oncolytics Biotech ADS signals hidden upside as Cohort‑5 data looms, offering long‑term investors a discounted entry point.

Oncolytics Biotech insider sale sparks investor concern as REOLYSIN shows early promise in melanoma and colorectal trials, but funding and clinical milestones remain uncertain.